Analyst Price Targets — DFTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 9:17 pm | — | Wolfe Research | $25.00 | $16.95 | TheFly | Definium Therapeutics initiated with an Outperform at Wolfe Research |
| January 29, 2026 11:29 pm | — | Jefferies | $30.00 | $17.24 | TheFly | Definium Therapeutics initiated with a Buy at Jefferies |
| January 29, 2026 12:40 pm | — | Robert W. Baird | $37.00 | $16.84 | TheFly | Definium Therapeutics price target raised to $37 from $16 at Baird |
| January 23, 2026 7:25 pm | — | RBC Capital | $36.00 | $17.40 | TheFly | Definium Therapeutics price target raised to $36 from $20 at RBC Capital |
| October 13, 2025 9:56 am | Ami Fadia | Needham | $28.00 | $11.81 | TheFly | Mind Medicine initiated with a Buy at Needham |
| March 7, 2025 12:35 pm | — | Robert W. Baird | $16.00 | $6.83 | TheFly | Mind Medicine price target lowered to $16 from $27 at Baird |
| September 16, 2024 8:07 am | Sumart Kulkami | Canaccord Genuity | $14.00 | $6.45 | StreetInsider | MindMed (MNMD) PT Lowered to $14 at Canaccord Genuity |
| June 5, 2024 6:14 am | Brian Abrahams | RBC Capital | $22.00 | $8.25 | StreetInsider | RBC Capital Reiterates Outperform Rating on MindMed (MNMD) |
| May 13, 2024 7:36 am | Francois Brisebois | Oppenheimer | $20.00 | $8.61 | StreetInsider | MindMed (MNMD) PT Lowered to $20 at Oppenheimer |
| November 16, 2022 6:10 am | — | RBC Capital | $5.00 | $2.86 | Benzinga | RBC Capital Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $5 |
Latest News for DFTX
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported its full-year 2025 financial results and provided business updates. “We are proud of the strong execution and momentum across our organization,…
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences: TD Cowen 46th…
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the…
Shares of Definium Therapeutics, Inc. (NASDAQ: DFTX - Get Free Report) have been assigned an average recommendation of "Buy" from the twelve research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have issued a strong
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DFTX.
U.S. House Trading
No House trades found for DFTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.